Literature DB >> 14669318

Epithelial cell proliferation and glandular atrophy in lymphocytic gastritis: effect of H pylori treatment.

Johanna M Mäkinen1, Seppo Niemelä, Tuomo Kerola, Juhani Lehtola, Tuomo J Karttunen.   

Abstract

AIM: Lymphocytic gastritis is commonly associated with Helicobacter pylori infection. The presence of glandular atrophy and foveolar hyperplasia in lymphocytic gastritis suggests abnormalities in cell proliferation and differentiation, forming a potential link with the suspected association with gastric cancer. Our aim was to compare epithelial cell proliferation and morphology in H pylori associated lymphocytic gastritis and H pylori gastritis without features of lymphocytic gastritis, and to evaluate the effect of H pylori treatment.
METHODS: We studied 14 lymphocytic gastritis patients with H pylori infection. For controls, we selected 14 matched dyspeptic patients participating in another treatment trial whose H pylori infection had successfully been eradicated. Both groups were treated with a triple therapy and followed up with biopsies for 6-18 months (patients) or 3 months (controls). Blinded evaluation for histopathological features was carried out. To determine the cell proliferation index, the sections were labeled with Ki-67 antibody.
RESULTS: Before treatment, lymphocytic gastritis was characterized by foveolar hyperplasia (P=0.001) and glandular atrophy in the body (P=0.008), and increased proliferation in both the body (P=0.001) and antrum (P=0.002). Proliferation correlated with foveolar hyperplasia and inflammation activity. After eradication therapy, the number of intraepithelial lymphocytes decreased in the body (P=0.004) and antrum (P=0.065), remaining higher than in controls (P<0.001). Simultaneously, the proliferation index decreased in the body from 0.38 to 0.15 (P=0.043), and in the antrum from 0.34 to 0.20 (P=0.069), the antral index still being higher in lymphocytic gastritis than in controls (P=0.010). Foveolar hyperplasia and glandular atrophy in the body improved (P=0.021), reaching the non-LG level.
CONCLUSION: In lymphocytic gastritis, excessive epithelial cell proliferation is predominantly present in the body, where it associates with foveolar hyperplasia and glandular atrophy. These characteristic changes of lymphocytic gastritis are largely related to H pylori infection, as shown by their improvement after eradication. However, some residual deviation was still seen in lymphocytic gastritis, indicating either an abnormally slow improvement or the presence of some persistent abnormality.

Entities:  

Mesh:

Year:  2003        PMID: 14669318      PMCID: PMC4612037          DOI: 10.3748/wjg.v9.i12.2706

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  23 in total

1.  Diagnostic criteria in lymphocytic gastritis.

Authors:  D A Lynch; M F Dixon; A T Axon
Journal:  Gastroenterology       Date:  1997-04       Impact factor: 22.682

2.  Treatment of Helicobacter pylori in patients with lymphocytic gastritis.

Authors:  S Niemelä; T J Karttunen; T Kerola
Journal:  Hepatogastroenterology       Date:  2001 Jul-Aug

3.  TIA1 and mast cell tryptase in food allergy of children: increase of intraepithelial lymphocytes expressing TIA1 associates with allergy.

Authors:  M Augustin; T J Karttunen; J Kokkonen
Journal:  J Pediatr Gastroenterol Nutr       Date:  2001-01       Impact factor: 2.839

4.  Sustained increase in gastric antral epithelial cell proliferation despite cure of Helicobacter pylori infection.

Authors:  H M El-Zimaity; D Y Graham; R M Genta; J Lechago
Journal:  Am J Gastroenterol       Date:  2000-04       Impact factor: 10.864

5.  Helicobacter pylori in dyspeptic patients: quantitative association with severity of gastritis, intragastric pH, and serum gastrin concentration.

Authors:  T Karttunen; S Niemelä; J Lehtola
Journal:  Scand J Gastroenterol Suppl       Date:  1991

6.  Helicobacter pylori infection and gastric carcinoma among Japanese Americans in Hawaii.

Authors:  A Nomura; G N Stemmermann; P H Chyou; I Kato; G I Perez-Perez; M J Blaser
Journal:  N Engl J Med       Date:  1991-10-17       Impact factor: 91.245

7.  Lymphocytic gastritis and associated small bowel disease: a diffuse lymphocytic gastroenteropathy?

Authors:  D A Lynch; G M Sobala; M F Dixon; A Gledhill; P Jackson; J E Crabtree; A T Axon
Journal:  J Clin Pathol       Date:  1995-10       Impact factor: 3.411

8.  Ten year follow up study of lymphocytic gastritis: further evidence on Helicobacter pylori as a cause of lymphocytic gastritis and corpus gastritis.

Authors:  S Niemelä; T Karttunen; T Kerola; R Karttunen
Journal:  J Clin Pathol       Date:  1995-12       Impact factor: 3.411

9.  Lymphocytic gastritis--relationship to Campylobacter pylori infection.

Authors:  M F Dixon; J I Wyatt; D A Burke; B J Rathbone
Journal:  J Pathol       Date:  1988-02       Impact factor: 7.996

10.  Helicobacter pylori causes hyperproliferation of the gastric epithelium: pre- and post-eradication indices of proliferating cell nuclear antigen.

Authors:  F Brenes; B Ruiz; P Correa; F Hunter; T Rhamakrishnan; E Fontham; T Y Shi
Journal:  Am J Gastroenterol       Date:  1993-11       Impact factor: 10.864

View more
  3 in total

1.  Correlation of serum antibody titres with invasive methods for rapid detection of Helicobacter pylori infections in symptomatic children.

Authors:  Khaled Abdulqawi; Abeer M El-Mahalaway; Amer Abdelhameed; Alsayed A Abdelwahab
Journal:  Int J Exp Pathol       Date:  2012-08       Impact factor: 1.925

2.  Topography, morphology, and etiology of lymphocytic gastritis: a single institution experience.

Authors:  Raymond H L Yip; Lawrence H Lee; Lik Hang Lee; David F Schaeffer; Basil A Horst; Hui-Min Yang
Journal:  Virchows Arch       Date:  2020-01-02       Impact factor: 4.064

3.  Histopathological classification and follow-up analysis of chronic atrophic gastritis.

Authors:  Yang-Kun Wang; Lan Shen; Tian Yun; Bin-Feng Yang; Chao-Ya Zhu; Su-Nan Wang
Journal:  World J Clin Cases       Date:  2021-06-06       Impact factor: 1.337

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.